Press Releases Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
0.7759 ^USD	+3.25%		+9.54%	-44.58%

11/06	Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic	CI
07/06	Canaccord Genuity Adjusts Price Target on Seres Therapeutics to $10 From $15, Maintains Buy Rating	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer	13/06	AQ
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08/06	AQ
SERES THERAPEUTICS ENTERS INTO MEMORANDUM OF UNDERSTANDING FOR VOWST ASSET SALE TO NESTLE HEALTH SCIENCE	07/06	AQ
Seres Therapeutics - Nestle Health Science agrees to acquire global rights to VOWST, product it launched in June 2023	07/06	AQ
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023	06/06	PR
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science	06/06	AQ
Seres Therapeutics: Q1 Earnings Snapshot	08/05	AQ
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	08/05	BU
Seres Therapeutics : Accelaration/Increase of Financial Obligation - Form 8-K	08/05	PU
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/05	BU
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024	06/05	BU
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04	AQ
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	09/04	BU
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	28/03	BU
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	20/03	AQ
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19/03	BU
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	05/03	BU
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024	28/02	BU
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference	27/02	BU
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz	26/02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Press Releases

Filters